Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.
Ben M EyckJ Jan B van LanschotMaarten C C M HulshofBerend J van der WilkJoel ShapiroPieter van HagenMark Ivo van Berge HenegouwenBas P L WijnhovenHanneke Wilma Marlies van LaarhovenGrard A P NieuwenhuijzenGeke A P HospersJohannes J BonenkampMiguel A CuestaReinoud J B BlaisseOlivier R BuschGeert-Jan M CreemersCornelis J A PuntJohn Th M PlukkerHenk M W VerheulErnst J Spillenaar BilgenMaurice J C van der SangenTom RozemaFiebo J W Ten KateJannet C BeukemaAnna H M PietCaroline M van RijJanny G ReindersHugo W TilanusEwout Willem SteyerbergAte van der Gaastnull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
The overall survival benefit of patients with locally advanced resectable esophageal or junctional cancer who receive preoperative chemoradiotherapy according to CROSS persists for at least 10 years.
Keyphrases
- locally advanced
- rectal cancer
- phase iii
- neoadjuvant chemotherapy
- squamous cell carcinoma
- phase ii
- phase ii study
- radiation therapy
- open label
- papillary thyroid
- minimally invasive
- clinical trial
- double blind
- coronary artery bypass
- study protocol
- patients undergoing
- squamous cell
- randomized controlled trial
- coronary artery disease
- free survival
- percutaneous coronary intervention
- atrial fibrillation
- liver metastases